COSCIENS Biopharma Inc.

What they do

COSCIENS Biopharma Inc. develops and commercializes therapeutic and nutraceutical products derived from natural sources, with a focus on oat-based ingredients such as oat-beta glucan, avenanthramides, and beta glucan from yeast. The company also operates through subsidiaries, including Aeterna Zentaris GmbH and Zentaris IVF GmbH, though the latter are being wound down. Its PGX Technology is being scaled up for commercial applications.

Revenue drivers

• Oat-based nutraceutical products — The company's pipeline includes oat-beta glucan, avenanthramides, and beta glucan from yeast, which are intended for the nutraceuticals market, but the filing does not provide a relative size or revenue contribution for these products.
• PGX Technology — PGX Technology is a proprietary platform being scaled up to commercial levels, but no specific revenue figures are disclosed in the excerpts.
• Active ingredients from natural sources — The company extracts, produces, and commercializes active ingredients from natural sources, but the filing does not break out segment-level revenue.

Recent performance

The filing is for the fiscal year ended December 31, 2025, but no specific revenue or net income figures are provided in the excerpts. The company mentions the decision to wind down Aeterna Zentaris GmbH and Zentaris IVF GmbH, with related insolvency filings, implying potential cost savings and accounting implications. As of December 31, 2025, the company had 3,183,330 common shares outstanding.

Strategy

The company's stated strategy includes developing and commercializing its patented technologies and value-driving products, with a focus on oat-based pipeline products and PGX Technology. Management plans to accelerate the scale-up of PGX Technology to commercial levels and to find new customers and partners. The wind-down of Aeterna Zentaris GmbH and Zentaris IVF GmbH is expected to reduce costs and improve focus on core nutraceutical and natural ingredient opportunities.

Risks

• Execution risk on strategic plans — The company's ability to execute on its strategic plans and find new customers and partners is uncertain, as noted in its forward-looking statements.
• Raw material sourcing — The company may face challenges in sourcing raw materials required to develop its oat-based products, which could disrupt production.
• Tariffs and trade barriers — Tariffs and other trade barriers could impact the company's costs and revenues, affecting its competitive position in target markets.
• Liquidity and financing — The company may need additional financing to fund its business activities, and there is no assurance that such financing will be available on acceptable terms.

Outlook

Management's outlook focuses on executing its strategy to develop and commercialize its oat-based pipeline products and scale up PGX Technology, with the goal of addressing unmet needs in the nutraceuticals market. The wind-down of the German subsidiaries is expected to result in cost savings and improved financial focus. The company also plans to pursue termination or suspension of its U.S. reporting obligations under applicable securities laws.